Govt expert panel accepts Covaxin phase-3 trial data

An expert panel of the country's central drugs authority has reviewed and accepted the phase-3 trial data of Bharat Biotech's COVID-19 vaccine Covaxin, sources said on Tuesday. According to the data submitted by the Hyderabad-based firm, the indigenously developed vaccine has shown 77.8 per cent efficacy in the trial conducted on 25,800 subjects, they said. The firm had submitted the results of its phase-3 trial efficacy data of Covaxin to the Drugs Controller General of India (DCGI) over the weekend, they added.